Table 2.
Dosing and cognitive testing schedule with age in days and standard deviations in parentheses
| Age | Pre-drug phase | Low-dose phase | Moderate-dose phase | Post-drug phase |
|---|---|---|---|---|
| 264.2 (17.3) | 379.8 (16.6) | 491.8 (16.6) | 603.9 (16.8) | |
| Two-object discrimination | ||||
| Placebo | 279.2 (20.5) | 390.2 (31.7) | 499.6 (26.9) | 618.9 (38.0) |
| Risperidone | 271.4 (12.9) | 395.7 (33.9) | 488.8 (14.4) | 621.7 (38.8) |
| Quetiapine | 289.6 (27.8) | 392.8 (17.7) | 525.8 (37.2) | 616.8 (17.7) |
| Learning set | ||||
| Placebo | 367.9 (17.0) | 452.6 (24.6) | 558.5 (24.7) | 621.4 (29.1) |
| Risperidone | 358.5 (12.9) | 446.8 (15.9) | 535.1 (32.7) | 628.2 (37.0) |
| Quetiapine | 371.8 (16.2) | 456.1 (31.0) | 577.2 (24.2) | 624.9 (18.1) |